

07-2004

7-04; 15:53 :DCB

EPO NL

:+3292802345

EP030335

005 19.07.2004 15:54:56

AMT 34 AMDT

Claims (retyped)

1. A vaccine composition suitable for administration to a vertebrate host, including man, which comprises:
 - (a) a polynucleotide vaccine component comprising at least one polynucleotide encoding at least one antigen, such that introduction of said formulation into said vertebrate host results in expression of a biologically effective amount of said antigen or antigens so as to induce a prophylactic or therapeutic immune response;
 - (b) a protein antigen vaccine component comprising at least one protein antigen selected from the group of model protein antigens and vaccine protein antigens; and
 - (c) a mineral-based, negatively charged adjuvant,further characterized in that said mineral-based, negatively charged adjuvant is prepared by preincubating or subsequently mixing with said at least one protein antigen vaccine component prior to formulating with said polynucleotide vaccine component.
2. A vaccine composition according to claim 1, wherein said mineral-based negatively charged adjuvant is an aluminium salt or a calcium salt.
3. A vaccine composition according to claim 2, wherein said aluminium or calcium salt is selected from the group consisting of aluminium phosphate, aluminium hydroxyphosphate, phosphate-treated aluminium hydroxide, calcium phosphate, calcium hydroxyphosphate, and phosphate-treated calcium hydroxide.
4. A vaccine composition according to any one of claims 1 to 3, wherein said group of model protein antigens range from acidic IEP proteins to alkaline IEP proteins.
5. A vaccine composition according to any one of claims 1 to 4, wherein said group of vaccine protein antigens includes a surface protein or a core protein of HBV, a de-toxified toxin from the bacteria *Clostridium tetani* (i. e. tetanus toxoid), a de-toxified toxin from the bacteria *Clostridium botulinus* (i. e. botulinus toxoid), and a de-toxified toxin from the bacteria *Corynebacterium diphtheriae* (i. e. diphtheria toxoid).
6. A vaccine composition according to any one of claims 1 to 4, wherein said group of vaccine protein antigens includes protein antigens derived from inactivated poliovirus.

AMENDED SHEET

9-07-2004

7-04; 15:53 DCB

EPO NL

; +3292802345

EP030338

006 19.07.2004 15:55:00

19-07-2004
15:55:00
19-07-2004
15:55:00

7. A kit comprising a vaccine composition as defined in any one of the claims 1-6 in a unit dose form for administration to a vertebrate recipient, including man.

8. Use of a mineral-based, negatively charged adjuvant as a component in a combined DNA/protein-based vaccine composition as defined in any one of claims 1-6.

9. A method for preparing a vaccine composition according to any of claims 1 to 6, wherein a mineral-based negatively charged adjuvant is preincubated or subsequently mixed with at least one protein antigen vaccine component prior to formulating with a polynucleotide vaccine component.

AMENDED SHEET